Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625

Obesity

Volumn 18, Issue 10, 2010, Pages 1952-1958

  Liebig, Michaela ^a   Gossel, Matthias ^a   Pratt, Jeremy ^b   Black, Mark ^b   Haschke, Guido ^a   Elvert, Ralf ^a   Juretschke, Hans Paul ^a   Neumann Haefelin, Claudia ^a   Kramer, Werner ^a   Herling, Andreas W ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; BENZODIAZEPINE DERIVATIVE; CANNABINOID 1 RECEPTOR; DRINABANT; HALOGENATED HYDROCARBON; NEUROLEPTIC AGENT; OLANZAPINE; SULFONAMIDE;

ANIMAL; ARTICLE; CALORIC INTAKE; CARBOHYDRATE DIET; DRUG ANTAGONISM; DRUG EFFECT; ENERGY METABOLISM; FAT INTAKE; FEMALE; HYPERPHAGIA; METABOLISM; OBESITY; OXIDATION REDUCTION REACTION; RAT; WEIGHT GAIN; WISTAR RAT;

ANIMALS; ANTI-OBESITY AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIETARY CARBOHYDRATES; DIETARY FATS; ENERGY INTAKE; ENERGY METABOLISM; FEMALE; HYDROCARBONS, HALOGENATED; HYPERPHAGIA; OBESITY; OXIDATION-REDUCTION; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; SULFONAMIDES; WEIGHT GAIN;

RATTUS; RATTUS NORVEGICUS;

EID: 77957126062     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2010.17     Document Type: Article

References (35)

1. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004;184:58-62.
2. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004;66:51-57.
3. Tschoner A, Engl J, Rettenbacher M, et al. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. Pharmacopsychiatry 2009;42:29-34.
4. Goudie AJ, Smith JA, Halford JC. Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol (Oxford) 2002;16:291-296.
5. Herling AW, Gossel M, Haschke G, et al. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab 2007;293:E826-E832.
6. van der Zwaal EM, Luijendijk MC, Adan RA, la Fleur SE. Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur J Pharmacol 2008;585:130-136.
7. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003;305:625-631.
8. Kuhlmann J, Neumann-Haefelin C, Belz U, et al. Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats. Diabetes 2003;52:138-144.
9. Meyer CW, Elvert R, Scherag A, et al. Power matters in closing the phenotyping gap. Naturwissenschaften 2007;94:401-406.
10. Klaus S, Münzberg H, Trüloff C, Heldmaier G. Physiology of transgenic mice with brown fat ablation: obesity is due to lowered body temperature. Am J Physiol 1998;274:R287-R293.
11. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 2005;181:80-89.
12. Fell MJ, Anjum N, Dickinson K, et al. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology (Berl) 2007;194:221-231.
13. Iossa S, Lionetti L, Mollica MP, Barletta A, Liverini G. Energy intake and utilization vary during development in rats. J Nutr 1999;129:1593-1596.
14. Arjona AA, Zhang SX, Adamson B, Wurtman RJ. An animal model of antipsychotic-induced weight gain. Behav Brain Res 2004;152:121-127.
15. Davoodi N, Kalinichev M, Korneev SA, Clifton PG. Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology (Berl) 2009;203: 693-702.
16. Minet-Ringuet J, Even PC, Valet P, et al. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry 2007;12:562-571.
17. Vestri HS, Maianu L, Moellering DR, Garvey WT. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007;32:765-772.
18. Graham KA, Perkins DO, Edwards LJ, et al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005;162:118-123.
19. Schmidt RF, Thews G. Physiologie des Menschen. Springer, 1997.
20. Gothelf D, Falk B, Singer P, et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002;159:1055-1057.
21. Ortega-Alvaro A, Gibert-Rahola J, Micó JA. Influence of chronic treatment with olanzapine, clozapine and scopolamine on performance of a learned 8-arm radial maze task in rats. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:104-111.
22. Thornton-Jones Z, Neill JC, Reynolds GP. The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. J Psychopharmacol (Oxford) 2002;16:35-37.
23. Virkkunen M, Wahlbeck K, Rissanen A, Naukkarinen H, Franssila-Kallunki A. Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study. Pharmacopsychiatry 2002;35:124-126.
24. Andersen SW, Clemow DB, Corya SA. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry 2005;66:1468-1476.
25. Blass DM, Chuen M. Olanzapine-associated hypothermia. Psychosomatics 2004;45:135-139.
26. McCullough L, Arora S. Diagnosis and treatment of hypothermia. Am Fam Physician 2004;70:2325-2332.
27. Goudie AJ, Cole JC, Sumnall HR. Olanzapine withdrawal/ discontinuationinduced hyperthermia in rats. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1500-1503.
28. Oerther S, Ahlenius S. Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat. J Pharmacol Exp Ther 2000;292:731-736.
29. Stefanidis A, Verty AN, Allen AM, et al. The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity (Silver Spring) 2009;17: 16-24.
30. Skouroliakou M, Giannopoulou I, Kostara C, Hannon JC. Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine. Nutrition 2009;25:729-735.
31. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353-359.
32. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001;22:565-572.
33. 3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol 2005;371:428-433.
34. Melis T, Succu S, Sanna F, et al. The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. Neurosci Lett 2007;419:231-235.
35. Fountaine R, Taylor A, Mancuso J, et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity, this issue (oby.2010.6).